Please login to the form below

Not currently logged in
Email:
Password:

GSK fails to find global buyer for OTC brand portfolio

Does £426m deal with Prestige Brands Holding for some US and Canada rights

GlaxoSmithKline (GSK) has sold the rights to several 'non-core' over-the-counter (OTC) products in the US and Canada to Prestige Brands Holdings for £426m.

The US-based company, which markets, sells and distributes OTC and household cleaning products to retail outlets, acquires the rights to the brands such as GSK's aspirin Ecotrin, pain reliever BC and heartburn treatment Tagamet.

GSK had originally intended to agree a single global deal for all the OTC products, including its weight loss treatment Alli, with US private equity firm Thomas H Lee Partners (THL) seen as the lead candidate.

So it still needs a European buyer for the products, and global rights to Alli remain on the table. Negotiations for these product licences, which GSK said brought in revenues of around £400m during 2010, remain ongoing.

Simon Dingemans, GSK's chief financial officer, said: "The disposal of our non-core consumer brands is about realising attractive value for shareholders as well as simplifying our ongoing consumer business and allowing it to focus on its priority brands and markets.”

The products acquired by Prestige Brands Holdings brought in £134m during 2010 and £98m in the first nine months of 2011.

GSK originally announced its intention to sell off the OTC products in April, 2011, claiming the lines lacked 'sufficient critical mass'.

It defined the three priorities of its consumer healthcare business as oral health, wellness/OTC and Nutrition, citing such products as Sensodyne and Panodol as its priority brands.

Andrew Witty, CEO of GSK, described its consumer business as a “key growth driver” but said the company had to focus on products with the “best prospects” for growth.

21st December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics